NCT07167992Not yet recruiting
Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in Pleurodesis
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
Pleural effusion is characterized by the accumulation of fluid in the pleural space, which typically contains about 10-20 mL of pleural fluid that is crucial for the movement of the lungs against the chest wall. This fluid closely resembles plasma but has a lower protein concentration, usually less than 1.5 gm/dL. It primarily originates from pleural capillaries and the interstitial spaces of the lung, and is reabsorbed through the lymphatic vessels in the parietal pleura, either via small openings known as stomas or through a process called transcytosis (1, 2). When the balance between fluid production and reabsorption is disrupted-often due to various pathogenic mechanisms-it can lead to pleural effusion. In such cases, effective management is essential. This study aims to conduct a thorough comparison of the two talc administration methods-TS and TI-using sterilized, large-particle, asbestos-free talc powder. By examining key outcome measures such as pleurodesis success rates, procedural morbidity, and length of hospital stay, the goal is to provide clinicians with evidence-based guidance to facilitate informed decision-making in the management of pleural effusions.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- First submitted
- 4 Sept 2025
- Start date
- 1 Feb 2026
- Primary completion date
- 30 Jan 2027
- Lead sponsor
- University of Health Sciences Lahore
- NCT number
- NCT07167992
What you commit to
- Study type: Interventional
- Planned participants: 160
- From 1 Feb 2026 to the primary completion date, 30 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients presenting with respiratory failure
Lab values
- Patients with evident chest infection with clinical or laboratory signs suggestive of parapneumonic effusions.
Age
- Patients younger than 12 years old
Other
- Female patients who are pregnant or lactating
- Patients with encysted or septated pleural effusions and pneumothoraces
- Patients complaining of dyspnea in spite of complete evacuation of pleural effusion or pneumothorax.
Who the study is looking for
- patients aged 12 years and older.
- Diagnosed with malignant pleural effusions or pneumothoraces.
- ECOG performance status of 0-2.
- Life expectancy of at least 3 months.
- Ability to provide informed consent.
- No contraindications to general anesthesia or conscious sedation.
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Services Institute of Medical Sciences (SIMS), Services Hospital Lahore Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.